Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Sangamo Therapeutics Inc is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Sangamo Therapeutics employs 413 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.32|
|52-week range||$8.13 - $19.43|
|50-day moving average||$9.13|
|200-day moving average||$10.35|
|Wall St. target price||$20.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.95|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-2.69%|
|1 month (2021-09-24)||-13.33%|
|3 months (2021-07-23)||-16.30%|
|6 months (2021-04-23)||-28.95%|
|1 year (2020-10-23)||-23.25%|
|2 years (2019-10-24)||-4.04%|
|3 years (2018-10-24)||12.35|
|5 years (2016-10-24)||121.87%|
|Revenue TTM||$137.7 million|
|Gross profit TTM||$-62,455,000|
|Return on assets TTM||-10.27%|
|Return on equity TTM||-28.29%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 10.5 million Sangamo Therapeutics shares held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 2.2% down from 10.7 million last month.
There are a few different ways that this level of interest in shorting Sangamo Therapeutics shares can be evaluated.
Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics shares currently shorted divided by the average quantity of Sangamo Therapeutics shares traded daily (recently around 958668.01099908). Sangamo Therapeutics's SIR currently stands at 10.91. In other words for every 100,000 Sangamo Therapeutics shares traded daily on the market, roughly 10910 shares are currently held short.
However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics shares, or, against the total number of tradable Sangamo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Sangamo Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0867% of the tradable shares (for every 100,000 tradable Sangamo Therapeutics shares, roughly 87 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sangamo Therapeutics.
Find out more about how you can short Sangamo Therapeutics stock.
We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $8.13 up to $19.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.6677. This would suggest that Sangamo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.